Evidence map›Paper›PMID 37501932›Full record

ArticleMediators of inflammation2023

LINC01088/miR-22/CDC6 Axis Regulates Prostate Cancer Progression by Activating the PI3K/AKT Pathway.

Jianwei Li, Xinghua Huang, Haodong Chen, Caifu Gu, Binyu Ni, Jianhua Zhou

Open access · goldAbstract read
In one paragraph

Article in Mediators of inflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. LINC01088 Targets miR-195-5p to Promote Proliferation and Migration and Reduce Apoptosis in the Inhibition of Carotid Artery Stenosis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jianwei Li *Department of Urology, Longgang District People's Hospital of Shenzhen, Guangdong 518000, China.
Xinghua Huang *Department of Urology, Longgang District People's Hospital of Shenzhen, Guangdong 518000, China.
Haodong ChenDepartment of Urology, Longgang District People's Hospital of Shenzhen, Guangdong 518000, China.
Caifu GuDepartment of Thyroid and Breast Surgery, Longgang Central Hospital, Shenzhen, Guangdong 518000, China.
Binyu NiDepartment of Pediatrics, Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong 518000, China.
Jianhua ZhouDepartment of Urology, Longgang District People's Hospital of Shenzhen, Guangdong 518000, China.ORCID https://orcid.org/0009-0008-9627-6517
Longgang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer (PCa) harms the male reproductive system, and lncRNA may play an important role in it. Here, we report that the LINC01088/microRNA- (miRNA/miR-) 22/cell division cycle 6 (CDC6) axis regulated through the phosphatidylinositide 3-kinases- (PI3K-) protein kinase B (AKT) signaling pathway controls the development of PCa. Methods: lncRNA/miRNA/mRNA associated with PCa was downloaded and analyzed by Gene Expression Omnibus. The expression and correlation of LINC01088/miR-22/CDC6 in PCa were analyzed and verified by RT-qPCR. Dual-luciferase was used to analyze the binding between miR-22 and LINC01088 or CDC6. Cell Counting Kit-8 and Transwell were used to analyze the effects of LINC01088/miR-22/CDC6 interactions on PCa cell viability or migration/invasion ability. Localization of LINC01088 in cells was analyzed by nuclear cytoplasmic separation. The effect of LINC01088/miR-22/CDC6 interaction on downstream PI3K/AKT signaling was analyzed by Western blot. Results: LINC01088 or CDC6 was upregulated in prostate tumor tissues or cells, whereas miR-22 was downregulated, miR-22 directly targets both LINC01088 and CDC6. si-LINC01088 inhibits the PCa process by suppressing the PI3K/AKT pathway. CDC6 reverses si-linc01088-mediated cell growth inhibition and reduction of PI3K and AKT protein levels. Conclusion: Our results demonstrate that the LINC01088/miR-22/CDC6 axis functions in PCa progression and provide a promising diagnostic and therapeutic target.

Indexed as

MicroRNAsProstatic NeoplasmsRNA, Long NoncodingCell Cycle ProteinsCell Line, TumorCell MovementCell ProliferationHumansMaleNuclear ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktCDC6 protein, humanCell Cycle ProteinsMicroRNAsMIRN22 microRNA, humanNuclear ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Long Noncoding

Identifiers

PMID37501932
PMCPMC10371595
OpenAlexW4384828789

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.